Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 66.63% is in line with its 5-year average of 66.45%, around the middle of its 5-year range (61.21%–71.95%).
0.13% below its 12-month average of 66.72%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 64.61%.
GROSS MARGIN
66.63%
GROSS MARGIN AVG TTM
66.72%
GROSS MARGIN AVG 3Y
67.50%
GROSS MARGIN AVG 5Y
66.45%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.13%
CURRENT VS 3Y AVG
-1.29%
CURRENT VS 5Y AVG
+0.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+61.70%
vs the sector median at left
SOPHiA GENETICS S.A.
Market Cap
$619.15M
Gross Margin
66.63%
TTM Avg
66.72%
3Y Avg
67.50%
5Y Avg
66.45%
Market Cap
$632.16M
Gross Margin
-58.05%
TTM Avg
20.98%
3Y Avg
10.49%
5Y Avg
14.13%
Market Cap
$634.30M
Gross Margin
84.52%
TTM Avg
76.56%
3Y Avg
85.05%
5Y Avg
87.20%
Market Cap
$638.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$597.55M
Gross Margin
99.76%
TTM Avg
98.92%
3Y Avg
99.03%
5Y Avg
96.38%
Market Cap
$596.01M
Gross Margin
54.62%
TTM Avg
54.27%
3Y Avg
52.72%
5Y Avg
52.86%
Market Cap
$584.48M
Gross Margin
35.58%
TTM Avg
39.19%
3Y Avg
43.45%
5Y Avg
55.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | 66.63% | 66.72% | 67.50% | 66.45% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 0.00% | 0.00% | 0.00% | 0.00% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -18.17% | 40.91% | 70.46% | 80.30% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -58.05% | 20.98% | 10.49% | 14.13% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 84.52% | 76.56% | 85.05% | 87.20% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 99.76% | 98.92% | 99.03% | 96.38% |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | 54.62% | 54.27% | 52.72% | 52.86% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | 35.58% | 39.19% | 43.45% | 55.13% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | 73.65% | 72.81% | 73.64% | 74.48% |
Gross Margin
66.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 64.61% |
| 2026-03-31 | 68.01% |
| 2025-12-31 | 67.68% |
| 2025-09-30 | 66.32% |
| 2025-06-30 | 66.97% |
| 2025-03-31 | 68.67% |
| 2024-12-31 | 68.25% |
| 2024-09-30 | 67.20% |
| 2024-06-30 | 68.17% |
| 2024-03-31 | 65.94% |
| 2023-12-31 | 69.80% |
| 2023-09-30 | 69.15% |
| 2023-06-30 | 66.74% |
| 2023-03-31 | 69.41% |
| 2022-12-31 | 71.95% |
| 2022-09-30 | 62.61% |
| 2022-06-30 | 65.31% |
| 2022-03-31 | 61.78% |
| 2021-12-31 | 62.45% |
| 2021-09-30 | 63.17% |
| 2021-06-30 | 61.21% |
| 2021-03-31 | 62.58% |
| 2020-12-31 | 62.41% |
| 2020-09-30 | 59.53% |
| 2020-06-30 | 67.04% |
| 2020-03-31 | 61.06% |
